Kinevant Sciences Discontinues Namilumab Development for Pulmonary Sarcoidosis Following Phase 2 Failure

Study Failure:
Kinevant Sciences announced that its Phase 2 RESOLVE-Lung study of namilumab failed to show a treatment benefit in patients with chronic active pulmonary sarcoidosis12.

Development Discontinuation:
Further development of namilumab for the treatment of sarcoidosis will be discontinued due to the lack of efficacy12.

Study Design:
The RESOLVE-Lung study was a randomized, double-blind, placebo-controlled study that enrolled 107 patients with pulmonary sarcoidosis. Patients received a once-monthly subcutaneous injection of namilumab or placebo for approximately six months2.

Primary Endpoint:
The primary endpoint of the study was the proportion of subjects with a Rescue Event during the double-blind period, which namilumab failed to meet12.

Secondary Endpoints:
Secondary efficacy endpoints, including change in percent predicted forced vital capacity, corticosteroid tapering success, and change in the patient-reported King’s Sarcoidosis Questionnaire, also failed to show a treatment benefit12.

Safety Profile:
The safety profile of namilumab in RESOLVE-Lung remained similar to previous studies12.

Future Research:
Kinevant is committed to publishing the results of RESOLVE-Lung to inform future sarcoidosis research12.

Sources:

1. https://www.globenewswire.com/news-release/2024/12/03/2990446/34323/en/Kinevant-Sciences-Announces-Topline-Results-from-Phase-2-RESOLVE-Lung-Study-of-Namilumab-in-Chronic-Active-Pulmonary-Sarcoidosis.html

2. https://www.biospace.com/press-releases/kinevant-sciences-announces-topline-results-from-phase-2-resolve-lung-study-of-namilumab-in-chronic-active-pulmonary-sarcoidosis